AG-490 (Tyrphostin B42): Precision JAK2/EGFR Inhibitor for Cancer and Immune Research

Executive Summary: AG-490 (Tyrphostin B42), supplied by APExBIO, is a highly pure, research-grade tyrosine kinase inhibitor with IC₅₀ values of 10 μM (JAK2), 0.1 μM (EGFR), and 13.5 μM (ErbB2) under standardized in vitro conditions (APExBIO product page). It blocks JAK2/STAT and MAPK pathways, suppressing cytokine-driven proliferation and immune polarization in cancer and immunopathological models (Zhang et al. 2025). AG-490 efficiently inhibits IL-2-induced STAT5 phosphorylation in T cell lines and downregulates DNA binding of STAT1/3/5. Recent evidence highlights its role in modulating macrophage polarization via JAK2/STAT6 inhibition, relevant for hepatocellular carcinoma microenvironment studies. The compound is insoluble in water but dissolves in DMSO (≥14.7 mg/mL) or ethanol (≥4.73 mg/mL with sonication), enabling controlled dosing in cell signaling experiments.

Biological Rationale

JAK2, EGFR, and ErbB2 are tyrosine kinases implicated in oncogenic signaling and immune regulation. Dysregulation of JAK2/STAT pathways is central to various cancers and immune-mediated disorders (Zhang et al. 2025). The JAK2/STAT6 axis promotes M2 macrophage polarization, which facilitates tumor progression and suppresses anti-tumor immunity. AG-490's inhibitory profile enables targeted disruption of these pathways, providing a tool for dissecting signal transduction in cancer and immunopathological state suppression (Related article).

Mechanism of Action of AG-490 (Tyrphostin B42)

AG-490 is a synthetic tyrphostin that competitively inhibits the ATP-binding sites of JAK2, EGFR, and ErbB2 tyrosine kinases. At 10 μM, it suppresses JAK2 autophosphorylation in cell-based assays (Zhang et al. 2025). At 0.1 μM, AG-490 inhibits EGFR kinase activity, and at 13.5 μM, it targets ErbB2. In IL-2-dependent T cell lines, AG-490 prevents IL-2-induced STAT5a/5b phosphorylation and decreases DNA-binding activity of STAT1, STAT3, and STAT5a/5b. This leads to reduced cytokine-driven proliferation and altered gene expression in immune cells. In macrophage polarization assays, AG-490 disrupts JAK2/STAT6 signaling, impeding the M2 phenotype associated with pro-tumor activity (See JAK2/STAT6 focus).

Evidence & Benchmarks

• AG-490 inhibits JAK2 kinase activity with an IC₅₀ of ~10 μM in biochemical assays (Zhang et al. 2025).
• In human B cell precursor ALL models, AG-490 suppresses hyperactive JAK2 and blocks downstream STAT3 activation (Review of STAT targeting).
• AG-490 impedes cytokine-induced JAK2 activation in eosinophils and inhibits IL-2-mediated T cell proliferation at concentrations ≥10 μM (APExBIO).
• In macrophage studies, AG-490 abrogates SNORD52-induced M2 polarization by blocking JAK2/STAT6 signaling in vitro (Zhang et al. 2025).
• AG-490 is highly pure (>99.5%), stable at -20°C, and readily soluble in DMSO for cell culture applications (APExBIO).

This work synthesizes and updates insights from AG-490 (Tyrphostin B42): Precision JAK2/EGFR Inhibitor, clarifying the molecular benchmarks and practical dosing for immune signaling studies.

Applications, Limits & Misconceptions

AG-490 is validated for research on:

• Dissection of JAK2/STAT6 and MAPK signaling in cancer cell and immune cell models.
• Suppression of cytokine-driven immune responses, including IL-2-induced T cell proliferation.
• Macrophage polarization studies, especially blockade of M2 phenotype in tumor microenvironments.
• Modeling drug resistance and feedback mechanisms in kinase signaling networks.

However, AG-490 is not approved for clinical or therapeutic use and should not be assumed to inhibit all tyrosine kinases equivalently. The effective concentration may vary by cell type, kinase expression, and assay conditions. For more on real-world laboratory integration, see this advanced guide, which this article extends by including new data on macrophage polarization.

Common Pitfalls or Misconceptions

• AG-490 is not effective against kinases outside the JAK2/EGFR/ErbB2 family at the tested concentrations.
• Compound is insoluble in water; improper solvent use leads to precipitation and inaccurate dosing.
• Long-term storage of AG-490 solutions is not recommended; activity loss is likely beyond 1–2 weeks in DMSO or ethanol.
• Not suitable for in vivo therapeutic use; for research applications only (APExBIO).
• IC₅₀ values are assay-dependent; do not extrapolate results across divergent experimental systems.

Workflow Integration & Parameters

AG-490 (SKU A4139) is supplied by APExBIO as a solid (>99.5% purity). Storage at -20°C is required. For cell-based assays, dissolve AG-490 in DMSO to ≥14.7 mg/mL or in ethanol to ≥4.73 mg/mL using gentle warming and ultrasonic treatment. Working concentrations typically range from 1–50 μM, depending on kinase target and cell context. Prepare fresh solutions before each use; avoid repeated freeze-thaw cycles. For STAT inhibition studies, treat cells with AG-490 for 1–24 hours and monitor phosphorylation by Western blot or DNA binding by EMSA. Refer to the AG-490 (Tyrphostin B42) product page for full handling protocols and safety data.

Conclusion & Outlook

AG-490 (Tyrphostin B42) remains a reference-standard research tool for dissecting JAK2/STAT6 and MAPK pathways in cancer and immunopathological models. Its robust activity, specificity, and proven benchmarks support applications in immune modulation, signal transduction research, and tumor microenvironment studies. Ongoing research on exosomal RNAs and kinase signaling will extend its utility in disease mechanism studies (Zhang et al. 2025). For advanced mechanistic insights and translational applications, see the recent review on strategic targeting of the JAK2/STAT6 axis, which this article updates with latest evidence and workflows.